Anti-Human Tenascin C Reference Antibody (ST2485, RUO) (HB274036)

Name: Anti-Human Tenascin C Reference Antibody (ST2485, RUO)
Brand: abinScience
SKU: HB274036
Price: 326 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB274036
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	ST2485
Biological activity	as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research [1].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Myotendinous antigen, Neuronectin, GMEM, Tenascin, Tenascin-C, TN-C, TNC, TN, Cytotactin, GP 150-225, Glioma-associated-extracellular matrix antigen, HXB, Hexabrachion, JI
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P24821
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	ST2485
Background	Tenascin (Tenascin-C/TNC) is a ~240 kDa protein. Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells. 1. Martina, E. et al. (2010) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 778-87. PMID: 19884327
References	1. Petronzelli, F., et al., (2005). Improved tumor targeting by combined use of two antitenascin antibodies. Clinical cancer research: an official journal of the American Association for Cancer Research, 11(19 Pt 2), 7137s–7145s. [HB274036]
Note	For research use only. Not suitable for clinical or therapeutic use.